BioMarin Pharmaceutical Inc. (BMRN) Guidance & Earnings Results

On 2026-10-06 BioMarin Pharmaceutical Inc. lowered guidance: "FY2026 GAAP Diluted EPS impact ~$1.55; Non-GAAP Diluted EPS impact ~$1.55; prior guidance did not reflect Alesta…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

BMRNBioMarin Pharmaceutical Inc.Follow BMRN — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 10.8B
P/E TTM: 151.2
Dividend yield: —
52-week: —
Next earnings: 3 Nov, in 9 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
6 Oct 26	Lowered	FY2026 GAAP Diluted EPS impact ~$1.55; Non-GAAP Diluted EPS impact ~$1.55; prior guidance did not reflect Alesta acquisition · full year
6 Aug 26	Raised	Full-year 2026 total revenue, VOXZOGO revenue, and non-GAAP diluted EPS guidance raised · full year
4 May 26	Raised	FY2026 revenue guidance raised to $3.825B-$3.925B, midpoint $3.875B, ~20% Y/Y growth · full year
23 Feb 26	Raised	Expects another year of strong financial performance and momentum in 2026 · full year
12 Jan 26	Reaffirmed	Excluding write-down, FY2025 Non-GAAP Diluted EPS guidance unchanged · full year
27 Oct 25	Raised	Full-year 2025 total revenues guidance raised at midpoint · full year
4 Aug 25	Raised	FY2025 total revenues raised to $3.125B-$3.2B from $3.1B-$3.2B; non-GAAP operating margin raised to 33%-34% from 32%-33%; non-GAAP diluted EPS raised to $4.40-$4.55 from $4.20-$4.40. · full year

BioMarin Pharmaceutical Inc. — questions

What guidance did BioMarin Pharmaceutical Inc. give?: On 2026-10-06: "FY2026 GAAP Diluted EPS impact ~$1.55; Non-GAAP Diluted EPS impact ~$1.55; prior guidance did not reflect Alesta acquisition"
When does BioMarin Pharmaceutical Inc. report earnings?: BioMarin Pharmaceutical Inc.'s next earnings report is expected on 2026-11-03.

Every figure on this page comes from BioMarin Pharmaceutical Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.